Literature DB >> 20632556

Significant dose can be lost by extended delivery times in IMRT with x rays but not high-LET radiations.

Michael C Joiner1, Nagaraju Mogili, Brian Marples, Jay Burmeister.   

Abstract

PURPOSE: To experimentally simulate IMRT delivery using two human cell models in vitro and test the hypothesis that a loss in effective dose resulting from the prolongation of megavoltage x-ray treatment delivery time would be greatly reduced in corresponding IMRT simulations using higher-LET radiation.
METHODS: The effect of prolonging the delivery time of a treatment fraction was investigated in vitro using human PC-3 prostate and HGL21 glioblastoma tumor cell lines. Cells were irradiated with x rays from a conventional linear accelerator or with neutrons from a clinical d(48.5)+Be radiotherapy beam and maintained at 37 degrees C throughout. The delivery time for six closely spaced doses, simulating six multiple-port segments, was varied from acute to 60 min for x-ray irradiation, and acute to 120 min for neutron irradiation. Cell survival was measured following summed doses for the six segments of 0.5-6 Gy for x rays and 0.16-2 Gy for neutrons, covering the most likely range of dose per fraction used in clinical radiotherapy.
RESULTS: Prolonging x-ray delivery time (from initiation of segment 1 to initiation of segment 6) from 5 to 45 min resulted in a loss in effective total dose (in equivalent 2 Gy multifraction treatments) of 5.6% in the PC-3 cell line and 11.7% in the HGL21 cell line. More clinically common prolongations of 5-30 and 5-15 min resulted in effective dose reductions of 3.8% and 1.7% for PC-3, and 7.3% and 2.9% for HGL21. A loss of less than 0.5% in effective dose was observed for prolongations up to 45 min of similarly effective neutron irradiation of PC-3 and HGL21 cells.
CONCLUSIONS: Prolonged delivery times of photon fractions could have a significant impact on treatment outcome especially for tumors with a low alpha/beta ratio and short repair halftime. These effects are significant at delivery times commonly associated with IMRT and are variable with cell type. X-ray IMRT should therefore always be planned to minimize dose-fraction delivery time. However, if IMRT treatments are delivered with high-LET radiation, this considerably reduces the dependence of the biological effect on fraction delivery time even out to 2 h.

Entities:  

Mesh:

Year:  2010        PMID: 20632556     DOI: 10.1118/1.3425792

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  6 in total

1.  Radiation repair models for clinical application.

Authors:  Roger G Dale
Journal:  Br J Radiol       Date:  2018-02-28       Impact factor: 3.039

2.  Impact of Decaying Dose-rate in Gamma Knife Radiosurgery.

Authors:  John W Hopewell; William T Millar; Ian Paddick; Christer Lindquist
Journal:  J Radiosurg SBRT       Date:  2013

3.  Application of the concept of biologically effective dose (BED) to patients with Vestibular Schwannomas treated by radiosurgery.

Authors:  John W Hopewell; William T Millar; Christer Lindquist; Håkan Nordström; Pär Lidberg; Jonas Gårding
Journal:  J Radiosurg SBRT       Date:  2013

Review 4.  Radiation therapy-induced metastasis: radiobiology and clinical implications.

Authors:  Benjamin J Blyth; Aidan J Cole; Michael P MacManus; Olga A Martin
Journal:  Clin Exp Metastasis       Date:  2017-11-20       Impact factor: 5.150

5.  Dosimetric Comparison and Evaluation of 4 Stereotactic Body Radiotherapy Techniques for the Treatment of Prostate Cancer.

Authors:  Jan Seppälä; Sami Suilamo; Mikko Tenhunen; Liisa Sailas; Heli Virsunen; Erna Kaleva; Jani Keyriläinen
Journal:  Technol Cancer Res Treat       Date:  2016-12-08

6.  Evaluation of inter- and intra-fraction 6D motion for stereotactic body radiation therapy of spinal metastases: influence of treatment time.

Authors:  Ahmed Hadj Henni; David Gensanne; Maximilien Roge; Chantal Hanzen; Guillaume Bulot; Elyse Colard; Sebastien Thureau
Journal:  Radiat Oncol       Date:  2021-08-30       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.